Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. - Wikidata - wikimedia - TriplyDB

Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.

Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.

http://www.wikidata.org/entity/Q40357320

about

Antibody therapies for lymphoma in children Antibody therapies for lymphoma in children Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead Burkitt lymphoma in adolescents and young adults: management challenges.Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.Pediatric lymphomas and histiocytic disorders of childhood Challenges of clinical trial design for targeted agents against pediatric leukemias.Bilateral burkitt lymphoma of the ovaries: a report of a case in a child with williams syndrome.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and CNS prophylaxis.Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.Immunotherapy targets in pediatric cancer.In search of targeted therapies for childhood cancer.Molecular profiling of childhood cancer: Biomarkers and novel therapies Advances in paediatric cancer treatment Immunotherapy in pediatric malignancies: current status and future perspectives Antibody therapy of pediatric B-cell lymphoma Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives Paediatric non-Hodgkin lymphoma - perspectives in translational biology Targeting developmental pathways in children with cancer: what price success?Immunotherapy for pediatric leukemia.Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.Antibody therapy for pediatric leukemia.New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.The future role of monoclonal antibody therapy in childhood acute leukaemias.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications.Novel approaches to pediatric leukemia treatment.

P2860

Q24186437-78F24121-A9F2-43C2-AD99-2EDA79236B53 Q24195106-35DFC115-9672-42E7-9BCB-06CD8BC50E35 Q26746934-205BC3F4-FCF9-4FF8-921D-69D187AD5ED2 Q26797513-B6045F88-C3C7-4B9C-858B-1615F548A3B0 Q30238965-1F1C94BD-35B7-4EC9-8A97-AAB2008E510E Q30240133-4AFDDA59-538B-4E33-B3D8-F2E37EF08475 Q30583310-34BE7833-4508-434E-9B9C-3452028AEBBF Q30847046-5DBE08F9-4D8A-4ADE-9271-A05F4FFF1A9E Q34344942-312B1EB7-5F20-498E-8A16-13ED5C7B645F Q34522797-F8584B8D-A5AA-4FF8-BEB5-C7D2D3742D31 Q34605894-F8E21B9D-B5B7-4CB7-99A0-323C1CD10E55 Q34839887-270E6DC5-FA81-422A-8103-B1261F2DABAE Q35043915-AB86AFB8-F687-4383-A3BC-EFA0FB11B33A Q35083003-91EFAE27-92D8-4E5F-862A-EFDD8F425CC8 Q35224485-F2D98C7D-CF6D-44A7-B68F-B980D98AC36F Q35237511-AF093912-2E28-48E5-8C7E-283A6D572DCD Q35667279-695AA1BC-AD50-47D2-B467-615059562B63 Q35687432-1369C43F-0B73-47B6-8A4B-77A53060A5F7 Q35963027-5EA19B62-B655-4F22-829B-8336C47BC77A Q35971029-9007E5E8-CDA7-4A51-B89A-6E37486FD502 Q35971733-2D008AEC-44DA-4F88-B050-D82CCFE95C83 Q36250783-C6CD7BD5-0E74-4E7D-83A5-95873AA77ADE Q36508630-670AEB0C-295D-4416-B022-5DD628BB2B7F Q36691818-3AFC2F87-F8CF-42E8-B268-87D61E05830B Q36732959-0574FB28-574C-446E-B3B0-ADF1DFDC2148 Q36804215-A1FD62B5-F6E3-4548-8BEC-5556DB2CAF05 Q36889143-18D63B86-09BE-4261-9EC5-C6610861BBBF Q36905620-9C382917-F2EA-47A3-9EE6-F9CB6A259746 Q36968163-761A571F-5EB3-4523-A9D2-1DF1721A8D01 Q37100817-FA5E0530-3314-49BE-9A95-3499D5F333A1 Q37718297-A3023620-9988-4E3C-B110-DCCCF3DCEB8C Q37725578-A8FC2827-B521-4F69-8830-DCD94AC598E4 Q37936432-4EA1485B-D522-4AB5-ACF0-D9CAAF829549 Q37977133-6FC5DC14-B033-472D-B4E5-439C2ED85860 Q38033600-8A58B580-CFD8-4F32-8C7F-EE0039496918 Q38097334-E0C9DA29-B2CB-4611-8223-9FDDE994F359 Q38097544-5030A617-ABB0-4B9A-9A74-8D2D48F5AD0E Q38112088-EE3500A0-03FF-4780-B089-EC4F168CFCB7 Q38205447-EF8E4820-C534-48E1-898E-7EEE90570513 Q38500371-B79457C7-A451-4A3D-B93F-F6DFA1849C87

P2860

Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.

http://www.wikidata.org/entity/Q40357320

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Phase II window study on ritux ...... lymphoma and Burkitt leukemia.

@en

type

label

Phase II window study on ritux ...... lymphoma and Burkitt leukemia.

@en

prefLabel

Phase II window study on ritux ...... lymphoma and Burkitt leukemia.

@en

P1433

Q40357320-90763615-C15B-4F04-AD17-AA6DCA18D77E

P1476

Q40357320-B6801C3F-B290-4A25-B0DF-1277EE789E13

P2093

Q40357320-0B5D32D3-CEFE-4861-B22E-1F7C16CCAB44

Q40357320-1A1C644C-8B0C-42D1-AD8B-E795C8C8BB95

Q40357320-3217EA16-B583-4EF6-88E8-C83CDB820788

Q40357320-473300DD-C8F3-4298-9A63-E6E74DAE6539

Q40357320-4A8D9020-6475-4CB8-BCE6-C3AC48FA39A8

Q40357320-4C0A982B-50C7-492B-9859-1962FA7DEE3D

Q40357320-52B6E0AD-9D30-4449-953F-41E939D40507

Q40357320-80FFC59E-4692-418C-87D6-E61780E51CFF

Q40357320-ABAE3AB8-7FF5-4B74-9E52-074856EDC7A8

Q40357320-C461F8AB-D3EB-45E4-A7FD-91B868461E82

P304

Q40357320-0F52EE9C-C7CC-4AC9-97AB-2B7E455F4E40

P31

Q40357320-98E06C49-F3CA-402D-8FAD-A86431AB3141

P356

Q40357320-70130DBA-24A5-46F2-9AF7-9F0B3FE93B31

P407

Q40357320-A9B3760D-2D2B-468A-ABDF-1E6E7E0F31FD

P433

Q40357320-CDDAFCC4-6057-4E8A-85FD-EE234819B696

P478

Q40357320-582FF0D1-1C9B-4CDF-8C42-5F1D53C49F99

P50

Q40357320-CD13CB3F-F700-479D-ADA0-5C3676E8178B

Q40357320-EE2B2424-CFE1-412F-A3B3-D52F95D51F94

P577

Q40357320-4DFBC724-7C05-44E5-9909-774FE5EEB80B

P698

Q40357320-B7D0BFB1-F692-4682-9FCD-4C2F79110D3C

P921

Q40357320-573E293A-D996-42C9-B9A2-C755937B8999

Q40357320-C81C7AF3-1CE8-4193-9882-0BD2ED8821D3

P356

JCO.2009.26.6791

P1433

Journal of Clinical Oncology

P1476

Phase II window study on ritux ...... lymphoma and Burkitt leukemia.

@en

P2093

Alfred Reiter

http://www.w3.org/2001/XMLSchema#string

Andishe Attarbaschi

http://www.w3.org/2001/XMLSchema#string

Andrea Meinhardt

http://www.w3.org/2001/XMLSchema#string

Arndt Borkhardt

http://www.w3.org/2001/XMLSchema#string

Berlin-Frankfurt-Münster group

http://www.w3.org/2001/XMLSchema#string

Birgit Burkhardt

http://www.w3.org/2001/XMLSchema#string

Christoph Klein

http://www.w3.org/2001/XMLSchema#string

Edita Kabickova

http://www.w3.org/2001/XMLSchema#string

Frank Berthold

http://www.w3.org/2001/XMLSchema#string

Gritta Janka-Schaub

http://www.w3.org/2001/XMLSchema#string

P304

3115-3121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.6791

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Klingebiel

Martin Schrappe

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20516455

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma